Literature DB >> 4942463

Effect of age and arteriosclerosis on the response of Parkinsonian patients to levodopa.

R B Godwin-Austen, S Bergmann, C C Frears.   

Abstract

Twenty-four patients with Parkinsonism were treated with levodopa for up to one year. Ten were aged under 65, 12 were aged 65 or over, and two were specifically included because they were considered to have arteriosclerotic Parkinsonism. These two patients showed no response to treatment. The 10 younger patients showed less clinical evidence of arteriosclerosis than the older ones, and responded significantly better to treatment with levodopa. Mean improvement was 61% in the younger group after 12 months' treatment and 28% in the older group. Improvement was greatest within three months of starting treatment. Abnormal movements which resulted from treatment with levodopa could be reduced with only slight loss of therapeutic benefit by the addition of tetrabenazine.

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 4942463      PMCID: PMC1799802          DOI: 10.1136/bmj.4.5786.522

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  13 in total

1.  Some Clinical Aspects of Parkinsonism [Abridged].

Authors:  H Garland
Journal:  Proc R Soc Med       Date:  1955-11

2.  Modification of Parkinsonism--chronic treatment with L-dopa.

Authors:  G C Cotzias; P S Papavasiliou; R Gellene
Journal:  N Engl J Med       Date:  1969-02-13       Impact factor: 91.245

3.  L-dopa in idiopathic parkinsonism.

Authors:  D B Calne; G M Stern; A S Spiers; D R Laurence
Journal:  Lancet       Date:  1969-11-08       Impact factor: 79.321

4.  L-dopa in postencephalitic parkinsonism.

Authors:  D B Calne; G M Stern; D R Laurence; J Sharkey; P Armitage
Journal:  Lancet       Date:  1969-04-12       Impact factor: 79.321

5.  Modification of chronic manganese poisoning. Treatment with L-dopa or 5-OH tryptophane.

Authors:  I Mena; J Court; S Fuenzalida; P S Papavasiliou; G C Cotzias
Journal:  N Engl J Med       Date:  1970-01-01       Impact factor: 91.245

6.  Importance and pathogenesis of abnormal movements during L-dopa therapy of Parkinson's disease.

Authors:  A Barbeau
Journal:  Neurology       Date:  1970-04       Impact factor: 9.910

7.  Treatment of parkinsonism with levodopa.

Authors:  M D Yahr; R C Duvoisin; M J Schear; R E Barrett; M M Hoehn
Journal:  Arch Neurol       Date:  1969-10

8.  Metabolic studies and clinical observations during L-dopa treatment of Parkinson's disease.

Authors:  M J Peaston; J R Bianchine
Journal:  Br Med J       Date:  1970-02-14

9.  L-Dopa (L-3,4-dihydroxyphenylanine)--its clinical effects in parkinsonism.

Authors:  M D Yahr; R C Duvoisin; M M Hoehn; M J Schear; R E Barrett
Journal:  Trans Am Neurol Assoc       Date:  1968

10.  L-dopa in Parkinsonism and the influence of previous thalamotomy.

Authors:  R C Hughes; J G Polgar; D Weightman; J N Walton
Journal:  Br Med J       Date:  1971-01-02
View more
  4 in total

Review 1.  The treatment of Parkinson's disease.

Authors:  R B Godwin-Austen
Journal:  Postgrad Med J       Date:  1977-12       Impact factor: 2.401

2.  Treatment of Parkinson's syndrome with L-DOPA on an out-patient basis.

Authors:  C Fehling
Journal:  Z Neurol       Date:  1972

3.  [Differential treatment of Parkinson's disease, with special reference to the possibility of iatrogenic disorders (author's transl)].

Authors:  W Gehlen
Journal:  Arch Psychiatr Nervenkr (1970)       Date:  1974-04-09

4.  Mental impairment in the elderly.

Authors:  H M Hodkinson
Journal:  J R Coll Physicians Lond       Date:  1973-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.